Predictive immunoinformatics reveal promising safety and anti-onchocerciasis protective immune response profiles to vaccine candidates (Ov-RAL-2 and Ov-103) in anticipation of phase I clinical trials.

PLoS One · 2024 · PMC11493244 · PMID 39432476

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

on the borderline of significanceno p-value reported

Antigenicity of both Ov-RAL-2 and Ov-103 were not found significant when tested by ANTIGENpro, and antigenicity score of both antigens by VaxiJen was also found on the borderline of significance cutoff (0.5).

also in 23 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.